medRxiv preprint doi: https://doi.org/10.1101/2021.08.26.21262379; this version posted August 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetati	y.
It is made available under a CC-B	Y 4.0 International license .

1	Estima	ating the global demand curve for a leishmaniasis vaccine: a generalisable approach based
2		on global burden of disease estimates
3	Saksh	i Mohan ¹ , Paul Revill ¹ , Stefano Malvolti ² , Melissa Malhame ² , Mark Sculpher ¹ , Paul M. Kaye ³
4	1.	Center for Health Economics (CHE), University of York, York, United Kingdom
5	2.	MMGH Consulting, Zurich, Switzerland
6	3.	York Biomedical Research Institute, Hull York Medical School, University of York, York,
7		United Kingdom
8		
9	Corresp	onding author: Sakshi Mohan; <u>sakshi.mohan@york.ac.uk</u> (ORCID iD: 0000-0002-1268-1769)
10		
11	Abstr	act
12	Backgr	ound
13	A pressi	ing need exists to develop vaccines for neglected diseases, including leishmaniasis. However,
14	the dev	elopment of new vaccines is dependent on their value to two key players – vaccine
15	develop	pers and manufacturers who need to have confidence in the global demand in order to
16	commit	to research and production; and governments (or other international funders) who need to
17	signal d	emand based on the potential public health benefits of the vaccine in their local context, as
18	well as	its affordability. A detailed global epidemiological analysis is rarely available before a vaccine
19	enters a	a market due to lack of resources as well as insufficient global data necessary for such an
20	analysis	. Our study seeks to bridge this information gap by providing a generalisable approach to
21	estimat	ing the commercial and public health value of a vaccine in development relying primarily on
22	publicly	available Global Burden of Disease (GBD) data. This simplified approach is easily replicable
23	and can	be used to guide discussions and investments into vaccines and other health technologies
24	where e	evidence constraints exist. The approach is demonstrated through the estimation of the
25	demano NOTE: Th	curve for a future leishmaniasis vaccine. is preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **Methodology/Principal findings**

28	We project the ability to pay over the period 2030-2040 for a vaccine preventing cutaneous and
29	visceral leishmaniasis (CL / VL), using an illustrative set of countries which account for most of the
30	global disease burden. First, based on previous work on vaccine demand projections in these
31	countries and CL / VL GBD-reported incidence rates, we project the potential long-term impact of
32	the vaccine on disability-adjusted life years (DALYs) averted as a result of reduced incidence. Then,
33	we apply an economic framework to our estimates to determine vaccine affordability based on the
34	abilities to pay of governments and global funders, leading to estimates of the demand and market
35	size. Based on our estimates, the maximum ability-to-pay of a leishmaniasis vaccine (per course,
36	including delivery costs), given the current estimates of incidence and population at risk, is higher
37	than \$5 for nearly half of the 24 countries considered, with a median value-based maximum price of
38	\$4.4-\$5.3, and total demand of over 560 million courses.
39	
40	Conclusion/Significance
41	Our results demonstrate that both the quantity of vaccines estimated to be required by the
42	countries considered as well as their ability-to-pay could make a vaccine for leishmaniasis
43	commercially attractive to potential manufacturers. The methodology used can be equally applied to
44	other technology developments targeting health in developing countries.
45	
46	Author summary

47 As of 2019, between 498,000 and 862,000 new cases of all forms of leishmaniasis were estimated to 48 occur each year resulting in up to 18,700 deaths and up to 1.6 million DALYs lost. Given low 49 treatment coverage, poor compliance and the emergence of drug resistance, challenges in

50 sustaining vector control strategies and the ability of parasites to persist in animal reservoirs

51 independent of human infection, an effective vaccine could significantly reduce the health and 52 economic burden of these diseases. However, commitment to the development of a new vaccine 53 requires a market signal from governments and global funders who in turn require better estimates 54 of the potential public health value of the vaccine. This study uses the development of a 55 leishmaniasis vaccine as a case study to illustrate a generalizable approach to estimating the 56 commercial and public health value of a technology relying primarily on publicly available GBD data. 57 More specifically, by projecting the potential public health impact of the rollout of a leishmaniasis 58 vaccine and translating this into monetary values based on the concept of health opportunity cost, 59 we estimate the demand curve for such a vaccine for an 11-year period between 2030 and 2040. At 60 an estimated global demand of over 560 million courses and a median value-based maximum price 61 of \$4.4-\$5.3, our results demonstrate that both the quantity of vaccines estimated to be required by 62 the countries considered as well as their ability-to-pay make the vaccine commercially attractive to 63 potential manufacturers.

64

65 Introduction

66 According to the Global Burden of Disease (GBD) study 2019, between 498,000 and 862,000 new 67 cases of all forms of leishmaniasis were estimated to occur each year resulting in up to 18,700 68 deaths and up to 1.6 million DALYs lost(1). Previously designated one of the most neglected among 69 neglected tropical diseases (NTDs) based on limited resources invested in diagnosis, treatment and 70 control(2), leishmaniasis accounts for 4% of the global DALY burden of NTDs and 5.5% of global NTD-71 related deaths. Furthermore, it is widely believed that these numbers grossly underestimate the real 72 burden of leishmaniasis as a result of underreporting and limited understanding of the true lifetime 73 impact of the disease(3-5).

74

The two most prevalent forms of leishmaniasis are localized cutaneous leishmaniasis (CL) and
 visceral leishmaniasis (VL). Despite the availability of effective treatment regimens, access to

77 treatment remains low(6,7). Given low treatment coverage, the occurrence of poor compliance and 78 the emergence of drug resistance(8), challenges in sustaining vector control strategies(9), and the 79 ability of parasites to persist in animal reservoirs, vaccines are widely regarded as having the 80 potential to significantly impact the health burden posed by leishmaniasis and to contribute to 81 regional leishmaniasis elimination campaigns (10). Between 2007 and 2013, nearly \$66 million was 82 invested by public sector and philanthropic funders towards leishmaniasis vaccine research and 83 development(11). Numerous vaccine candidates have been evaluated in preclinical models of 84 disease, but few have progressed to clinical trial stage(11). Currently, only one therapeutic clinical 85 trial is ongoing (12), and a genetically attenuated live *L. major* vaccine is due to be manufactured for 86 use in a clinical trial in 2021(13,14). 87 88 However, it is not enough just to develop a clinically effective vaccine. Rather, the vaccine also needs 89 to be affordable and suitable for delivery and administration in health systems. In particular, for a 90 vaccine to be produced and used, it needs to offer value to two key players: vaccine developers and 91 manufacturers who need to have confidence in global demand in order to commit to research and 92 production; and governments (or other international funders) who need to be sure of the potential 93 public health benefits of the vaccine in their local context, as well as affordability of the vaccine, in 94 order to signal demand. 95 96 This study seeks to fill this information gap about the commercial value proposition and likely

97 demand for a future leishmaniasis vaccine. This evaluation of a vaccine's potential economic value 98 can also help shed light on key targets for vaccine development and manufacturing plans such as 99 efficacy targets, target population groups/geographies, upper bound for manufacturing costs (and 100 required scale of manufacturing), and target market size while the vaccine is under development.

101

102 More generally, this study seeks to develop a simplified and generalizable framework which employs

103 publicly available burden of disease data to project the affordability, market size and public health

104 value of new interventions in order to inform and spur continued product development that can

- 105 improve health in low and middle-income countries (LMICs).
- 106

107 Methods

108 General approach

109 This study assesses the value associated with the introduction of a vaccine to prevent CL / VL. Value 110 is assessed in terms of the vaccine's potential impact on mortality and morbidity taking into account 111 its affordability within an illustrative set of countries in which the disease in endemic. First, based on 112 previous work on vaccine demand projections in these countries(14) and CL / VL incidence rates(1), 113 we project the potential long-term impact of a leishmaniasis vaccine on disability-adjusted life years 114 (DALYs) averted as a result of reduced incidence. Ideally, such an analysis would require a detailed 115 modeling of the disease epidemiology, disease dynamics, and health system capabilities of each 116 country under consideration. However, such models are not currently available for most countries 117 but planning for vaccine research and manufacturing needs to continue in their absence. Therefore, 118 we sought to develop a simplified approach, which uses publicly available data on disease incidence 119 and burden and population growth projections to assess the public health value of a future vaccine. 120 121 Second, we apply a health economic framework to our estimates of the future health impact of a

122 vaccine to determine the vaccine's affordability based upon the abilities to pay of governments and

123 global funders, leading to estimates of the demand and market size in this illustrative set of

124 countries. All monetary values are presented in 2019 US Dollars (USD).

125

126 Geographic focus

127 The analysis in this paper is focused on a representative sample of 24 countries belonging to a range 128 of income levels(15), geographic regions, type of endemic leishmaniasis, and Gavi, The Vaccine 129 Alliance (GAVI) support status(16) (Table 1). In 2019, these countries together represented 80% of 130 the global DALY burden of CL and VL, and 70% and 82% of the global incidence of CL and VL 131 respectively (1). 132 133 Vaccine efficacy and health effects 134 In the absence of a rigorous epidemiological model, we project the health effect of a vaccine using 135 the following estimates: i) total population susceptible to the disease (or population at risk); ii) 136 incidence of the disease among the population at risk; iii) per person burden of disease; and iv) 137 vaccine coverage and efficacy. This sub-section describes how these estimates were obtained and 138 used. 139 140 Environmental factors that affect the relationship between hosts, vectors (human, animal or sandfly) 141 and the reservoir determine the risk of leishmaniasis in the population. Malvolti et al. (2021)(14) 142 draw upon WHO Leishmaniasis country profiles as well as Pigott et al. (2014) (17) to project the size 143 of the population at risk for leishmaniasis-endemic countries until 2040 using 5-year population 144 growth projections from UN/DESA(18). The age-wise composition of the population at risk was 145 based on projection from the World Population Prospects report(19). 146 147 Incidence estimates were obtained from the Global Burden of Disease (GBD) study in 2019(1). These 148 were converted into incidence rates specific to populations at risk for 2019 by dividing the incidence 149 by the size of the population at risk (note that this assumes that no one outside the main population

150 at risk contracts the disease) for the different age groups included in the vaccine demand projections

- 151 in Malvolti et al. (2021)(14), namely 0-4 years, 5-14 years, and 15-29 years old. In the absence of
- 152 epidemiological projections of leishmaniasis incidence and given that there has not been a

153 significant decline in incidence over the last five years(20), we make the assumption that the 154 incidence rate among the population at risk remains constant between 2019 and 2040. Note that for 155 countries with anthroponotic VL transmission (i.e. Bangladesh, India, Nepal, Somalia, South Sudan 156 and Sudan), where VL is projected to be eliminated by Malvolti et al. (2021) (14) through existing 157 measures and deployment of a vaccine, we assume that in the absence of vaccine introduction, the 158 population at risk would continue to grow at the 5-year population growth rate from UN/DESA(18). 159 160 Similarly, the per person DALY burden of the disease was obtained from the 2019 GBD study for 161 each country and age group considered by dividing the relevant total DALY burden by the incidence, 162 given that the average duration of both CL and VL is less than a year(21). The 2019 values of the 163 epidemiological parameters used are shown in **Table 2**. This approach was taken due to the lack of 164 country-level data on the per-case DALY burden of the disease. We considered it important to use 165 country-level estimates due to the disparity between countries(2) in terms of clinical and 166 epidemiological presentations, comorbidities, treatment coverage, and fatality rates. 167 168 Based on previously developed vaccines(22), efficacy was assumed to be 75% in the base case 169 (based on the efficacy of previously researched leishmanization methods(22,23)). However, an 170 efficacy range between 50% and 95% is considered under sensitivity analysis. The duration of the 171 efficacy was assumed to be 10 years and an annual discount rate of three percent applied to health 172 gains in the future. 173 174 **Quantity of vaccines demanded** 175 Quantity demanded or demand here refers to the total vaccines projected to be required by a 176 country in a given year based on the target population at risk and rollout constraints, regardless of

- 177 market price. The vaccine demand projections are based on Malvolti et al. (2021)(14). This assumed
- 178 a dual vaccine delivery strategy, including a catch-up campaign at the start followed by rollout in a

179	routine immunization program. Routine immunization includes two age groups - 0-4 years, and 5-14
180	years. The catch-up campaign for CL includes two groups - 5-14 years, and 15-29 years; and for VL
181	only the 5-14 years age group was assumed to be targeted. Coverage estimates (those vaccinated as
182	a percentage of those targeted) are based on current vaccines with similar vaccination rollout
183	strategies (see Malvolti et al (2021)(14) for details) . Country-wise vaccine demand projections by
184	age are provided in Supplementary table 1 .
185	
186	Health economic analysis – global demand for a leishmaniasis vaccine
187	We assume that a heath intervention should be provided if it produces more health than could be
188	generated elsewhere in the health care system with the same resources (i.e. the benefits exceed the
189	opportunity costs). For every DALY averted (or QALY gained) from a new intervention, a health
190	system should pay no more than the cost at the margin at which it is already able to avert a DALY
191	from existing interventions (i.e. the marginal productivity; sometimes estimated as a cost-
192	effectiveness threshold (CET)). This approach, previously applied in country-specific studies(24,25),
193	allows us to estimate the maximum ability-to-pay, or the value-based maximum price, for a
194	leishmaniasis vaccine with a given efficacy. A country would demand the required number of
195	courses of the vaccine(14) if the price offered by the manufacturer is below their value-based
196	maximum price, and none if the global market price is above their value-based maximum price. Note
197	that our ability to pay estimates are inclusive of implementation costs incurred for the rollout of the
198	vaccine, i.e. the ability to pay for the medical product itself can be calculated by countries by
199	subtracting their local implementation costs from our estimates.
200	
201	To determine a price at which a country can afford the hypothetical vaccine requires an estimate of
202	the CET to reflect marginal productivity. We use the 'health budget opportunity cost' approach(26)
203	for CET estimates. A country government may choose to fund the vaccine only if it generates more

204 health than that which would be forgone if its limited health budget is redirected from existing

205	interventions to the vaccine. Country-level CETs have previously been estimated until 2040 by Lomas
206	et al. (2021)(27) based on historical estimates (28) of the marginal productivity of the different
207	countries' health systems. For countries for which these estimates were missing, CETs were
208	projected as an appropriate percentage of the projected GDP per capita(29) based on Ochalek et al.
209	(2020)(30). Country-level CET estimates used here are provided in Supplementary table 2 .
210	
211	In addition to averting DALYs through reduced infections, the vaccine would also reduce system
212	treatment costs which in turn would indirectly increase the ability to pay for the vaccine. The actual
213	reduction in treatment costs for the infected population depends on the expected coverage of
214	treatment, which in most countries would be less than 100%. In the absence of data on
215	leishmaniasis treatment coverage, we project the value-based maximum price under the
216	assumptions of both 0% and 100% treatment coverage to represent its upper and lower bounds.
217	
218	We assume an average treatment cost per VL case of \$541 based on Carvalho et al. (2017) (31). This
219	estimate includes the average cost through the lifecycle of treatment including pre-diagnosis
220	consultation, drug therapy, hospitalization and ambulatory care until post-treatment consultations.
221	Note that the drug therapy costs are based on the proportion of VL cases treated with meglumine
222	antimoniate, liposomal amphotericin B or amphotericin B deoxycholate respectively in Brazil in
223	2014. The average treatment cost per CL case is assumed to be \$57.6 based on Rodriguez et al.
224	(2019)(32). This estimate is based on the cost of the drug used (Intralesional pentavalent antimonials
225	(ILPA)) and staff time costs for CL treatment in Bolivia.
226	
227	Using these concepts, we were able to calculate the value-based maximum price for a course of the
228	leishmaniasis vaccine that each country is able to pay during each year of rollout, given the potential

- health benefit provided by the vaccine, and the country's CET (Box 1, equation 1). The demand for
- 230 vaccines for both CL and VL prevention and the ability-to-pay for each target use case (CL prevention

- and VL prevention) are aggregated to derive each country's global ability-to-pay for the vaccine (Box
- 232 1, equation 3).
- 233
- 234 Combined with the vaccine courses estimated to be required for each country, these are used to
- construct global demand curves for the vaccine during the 11-year period between 2030 and 2040.
- 236 For this purpose, we estimate the average value-based maximum price over 11 years, by dividing the
- 237 sum of the maximum resources which could be committed towards the leishmaniasis vaccine during
- each year (price times demand) by the aggregate demand between 2030 and 2040.
- 239

Box 1: Equations to estimate countries abilities to pay for a leishmaniasis vaccine

The value-based maximum price or ability-to-pay for a course of a leishmaniasis vaccine that each country is able to pay is estimated using the following formula:

$$p_{i,t,\alpha} = \frac{CET_{i,t} \Delta DALY_{i,t,\alpha} + \Delta T_{i,t,\alpha}}{q_{i,t,\alpha}},$$
(1)

$$\Delta DALY_{i,t,\alpha} = \sum_{\beta} \left[\Delta I_{i,t,\alpha,\beta} \sum_{n=0}^{N} \frac{\Delta DALY_{pp_{i,\alpha,\beta}}}{(1+r)^{n}} \right]$$
$$\Delta T_{i,t,\alpha} = \theta \sum_{n=0}^{N} \frac{\Delta I_{i,t,\alpha} T_{pp_{\alpha}}}{(1+r)^{n}}$$

$$\alpha = \{CL, VL\}$$

Where i = country

t = year of vaccination

 β = age groups-- 0-4 years, 5-14 years, 15-29 years

n = year of vaccine efficacy

N = *Number of years for which the vaccine is effective*

r = annual discount rate

p = Value-based price for a course of the vaccine

CET = Cost-effectiveness threshold (\$/DALY averted)

△DALY = Total DALYs averted from the reduction in CL-related/VL-related mortality

△DALY_pp = Change in DALYs per person infected with CL/VL

I = Change in CL/VL incidence as a result of the administration of the vaccine

T = Direct treatment cost of CL/VL

T_pp = Direct treatment cost per case of CL/VL

q = demand for the vaccine

 θ = coverage of leishmaniasis (CL and VL) treatment

To obtain the aggregate demand curve for the period 2030-2040, we obtain the aggregate

demand for vaccine courses and the average value-based maximum price for each country across

the target use cases as follows:

$$Q_i = \sum_{\alpha} \sum_{t} q_{i,t,\alpha}$$
(2)

$$\bar{p}_i = \frac{\sum_{\alpha} \sum_t p_{i,t,\alpha} q_{i,t,\alpha}}{Q_i}$$
(3)

Where

 Q_i = country i's aggregate demand for the vaccine between 2030 and 2040

 $\bar{p_i}$ = Average value-based price for a course of the vaccine for country i for the period under

consideration

240

241 Sensitivity Analysis

We evaluate the sensitivity of the projected global demand curves to three factors - i) vaccine
efficacy, ii) contributions from GAVI, and iii) adjustment for underreporting of leishmaniasis
incidence.

245

Under the first sensitivity analysis, the value-based maximum prices and global demand curves are
reevaluated for vaccine efficacy rates of 50% and 95%.

248

249 Sensitivity analysis is also carried out to assess the effect on global demand curves with GAVI 250 contribution towards countries which are expected to be eligible for support between 2030 and 251 2040 based on GDP per capita projections(29) using GAVI's criterion for support as of 2019(16). We 252 assume that a country is eligible for GAVI support during the 11 years under consideration if its 253 projected GDP per capita between 2026 and 2028 is under \$1580 (i.e. the country is either in the 254 initial self-financing or preparatory transition phase) or if its GDP per capita has been greater than 255 \$1580 for 5 years or less between 2022 and 2028 (i.e. the country is in the accelerated transition 256 phase). Given GAVI's current portfolio of vaccines, we expect GAVI's maximum ability to pay for 257 vaccines to be higher than that of some of the countries eligible for support. Based on previous work 258 on GAVI's willingness to pay for the rotavirus vaccine(33), we assume GAVI's cost effectiveness 259 threshold to be \$285 in 2019 USD. Therefore, under this sensitivity analysis, we re-estimate the 260 demand curve for a leishmaniasis vaccine by increasing the CET value for countries eligible for GAVI 261 support to \$285 if their own CET is lower in a given year. Country-level GAVI support projections are 262 provided in Supplementary table 3. 263

Finally, we also assess the potential effect of adjusting for the underreporting of cases on the valuebased maximum price, using estimates from Alvar et al. (2012)(34) of CL and VL underreporting by factors in the ranges 3.2-5.7 and 3.5-6.7 respectively (globally).

267

268 **Results**

269 Calculation of value-based maximum price

- 270 We calculated the country-wise value-based maximum price per course of the leishmaniasis vaccine
- and total demand based on equations 1,2 and 3, presented in tabular format (**Table 3**) and in the
- form of a demand curve for the illustrative set of 24 countries (Figure 1). As expected, the median
- 273 value-based maximum price under the assumption of full coverage of CL and VL treatment is higher
- 274 (by 19% on average) than under the assumption of no provision of treatment. This is because any
- treatment expenses saved through reduced incidence increase a country's ability to pay for the
- vaccine. The median value-based maximum price for the illustrative set of countries is \$4.4 and \$5.3
- 277 under the assumption of 0% and 100% treatment coverage respectively.
- 278 <Figure 1: Illustrative global demand curve for a leishmaniasis vaccine (with 75% efficacy) between
- 279 2030 and 2040>
- 280

281 Sensitivity analysis

282 Sensitivity to vaccine efficacy

283 The estimated prices in the above scenario assume a vaccine efficacy of 75% in preventing CL / VL. 284 Since vaccines against leishmaniasis are still under development or under testing, the actual efficacy 285 is unknown. We therefore also consider the effect of a change in vaccine efficacy on value-based 286 maximum prices (Figure 2). At an efficacy of 95%, the vaccine would prevent a larger number of 287 cases of CL / VL, averting more DALYs, and allowing countries to be able to pay a higher price at the 288 margin per course. This shifts the demand curve upwards from the earlier scenario assuming 75% 289 efficacy. Similarly, a lower efficacy of 50% shifts the demand curve downwards. More specifically, 290 the median value-based maximum price falls from \$4.4 to \$3.4 under the assumption of 0% 291 treatment coverage and from \$5.3 to \$3.8 under the assumption of 100% treatment coverage when

- the efficacy falls from 75% to 50%. At 95% efficacy, the median values rise to \$5.5 and \$6.5
- respectively (Table 4).
- 294 <Figure 2: Sensitivity of value-based maximum price to vaccine efficacy: (i) assuming treatment
- 295 coverage = 0%, (ii) assuming treatment coverage = 100%>
- 296
- 297 Impact of GAVI support for vaccine introduction
- 298 The results described above treat countries as independent buyers of the vaccine whose ability to
- 299 pay per vaccine course depends on their respective CET. However, international donors are often
- 300 able to ensure the expansion of important health interventions to low and lower-middle income
- 301 countries even when these may be locally cost-ineffective as a result of budget constraints. We
- 302 consider the effect of future GAVI funding of a potential leishmaniasis vaccine for countries eligible
- 303 for its support based on current criteria(16). We project that 11 of the 24 countries in our illustrative
- 304 list will be in one of the GAVI support phases (Supplementary table 3), of which six countries have a
- 305 CET lower than \$285 in 2030. Using a CET of \$285/DALY averted for these six countries, provides an
- 306 alternate demand curve (**Figure 3**). The mean value-based price nearly doubles under both
- 307 treatment coverage scenarios (Table 4).
- 308 <Figure 3: Illustrative global demand curve for a leishmaniasis vaccine (with 75% efficacy) between
- 309 2030 and 2040 including GAVI support>
- 310

311 Sensitivity to underreporting

- 312 The final sensitivity analysis adjusting for underreporting increases the median ability to pay to \$14.9
- 313 \$18.2 under the assumption of underreporting by a factor of 3.2 and 3.5 for CL and VL,
- respectively. These figures increase to \$27.4 \$33.4 when the upper bound underreporting factors
- 315 of 5.7 and 6.7 are applied for CL and VL respectively (Figure 4, Table 4).
- 316 <Figure 4: Sensitivity of value-based maximum price to underreporting: (i) Low underreporting
- 317 estimate , (ii) High underreporting estimate>

318 **Discussion**

319 This study has sought to provide a generalizable approach to estimating the commercial and public 320 health value of new technologies in development relying primarily on publicly available GBD data. 321 This simplified approach is easily replicable and can be used to guide discussions and investments 322 into health technology development, particularly in low and middle-income countries (LMICs), which 323 face significant constraints in acquiring and generating evidence compared with higher-income 324 countries. 325 326 The utility of this approach is demonstrated by projecting the economic feasibility of a leishmaniasis 327 vaccine based on currently available estimates of cost-effectiveness thresholds based on marginal 328 productivity, disease incidence and burden of disease. While other studies have previously tried to 329 estimate the cost-effectiveness of vaccines (35,36) and the monetary value of health 330 technologies (24,25), our approach is novel for its global focus and simplicity as well as the 331 incorporation of practical considerations including a realistic timescale of when the product is 332 expected to be available for distribution, gradual rollout and an evolving expected marginal 333 productivity of health systems. 334 335 Our results demonstrate that both the quantity of vaccines estimated to be required by the 336 countries considered, which represent a majority of the global burden of disease from leishmaniasis, 337 as well as their ability-to-pay make the vaccine commercially attractive to potential manufacturers. 338 The global demand stands at over 560 million courses, and the value-based maximum price per 339 course, given the current estimates of incidence and population at risk, is higher than \$5 for nearly 340 half of the 24 countries considered. Assuming a full course of two doses and an expected 341 manufacturing cost of \$2-3 per dose, based on adenovirus vaccines (37) similar to ChAd63-KH (the 342 only leishmaniasis vaccine currently recruiting into clinical trial(12)), a leishmaniasis vaccine of this 343 type would be commercially viable. The wide range of value-based maximum prices across different

344 countries also presents an opportunity for differential pricing to secure wide access. With possible 345 future contributions from GAVI considering its current willingness to pay for the rotavirus 346 vaccine(33), we estimate that the global demand curve would move further upwards. A similar 347 upward effect in abilities to pay is observed with adjustment for underreporting. 348 349 It should be noted that the prices presented above represent the maximum full health system cost 350 per vaccinated individual that countries can afford in the future. In other words, in order to 351 determine the value-based maximum price for the vaccine itself, countries will also need to consider 352 the number of doses required per course as well as the implementation costs. We have not included 353 implementation costs in our calculations because of the vast uncertainty in these costs and 354 variability across settings(38). These costs could make the vaccine unaffordable for some countries. 355 Furthermore, the quality of the underlying data on disease demographics, burden of disease, vaccine 356 rollout projections as well as the lack of treatment coverage data impose uncertainty around our 357 results. 358

359 However, we believe that overall our projections underestimate the ability to pay for a leishmaniasis 360 vaccine for a range of reasons including the exclusion of post-kala-azar dermal leishmaniasis (PKDL) 361 and its effect on VL transmission(39), exclusion of disease dynamics or transmission effects, 362 exclusion of psychosocial and mental health effects of the disease (which could amount to six times 363 the current estimate of DALY burden for CL (40)), and exclusion of treatment cost for leishmaniasis-364 HIV coinfection (which would increase the treatment cost per VL case by up to four times (31)). 365 Updating our assumptions based on a combination of all these factors could increase our estimates 366 of maximum ability to pay. However, there are several other sources of uncertainty, imposed by a 367 continuously evolving health sector landscape, which can only be addressed by updating these 368 estimates as and when updated information becomes available. Therefore, our demand and price 369 projections are far from definite but shine a light on important data gaps and uncertainties in

- 370 characterizing the leishmaniasis epidemic, addressing which will be crucial to better understanding
- 371 the future value of a vaccine against these diseases.
- 372
- 373 With better data, a full epidemiological model capturing disease dynamics should form the basis of
- 374 projections of the public health value of potential technologies. Such analysis is rarely feasible
- before a product enters a market due to lack of resources as well as global data on necessary
- 376 parameters. Our framework overcomes these challenges, albeit through various simplifications, and
- 377 we suggest that our results can be used to guide investments into improving the data available on
- 378 leishmaniasis. In addition, our results should help set in motion global discussions on the public
- 379 health value and commitment towards a leishmaniasis vaccine and help direct vaccine target
- 380 product profiles to ensure economic feasibility.
- 381

382 **References**

- 1. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 2019)
- 384 Data Resources [Internet]. IHME. 2020 [cited 2021 Apr 1]. Available from:
- 385 http://ghdx.healthdata.org/gbd-2019
- 386 2. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to
- 387 leishmaniasis [Internet]. Vol. 2, PLoS Neglected Tropical Diseases. PLoS Negl Trop Dis; 2008
- 388 [cited 2021 Apr 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/18958165/
- 389 3. Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-Serrano Á, et al. A
- 390 new perspective on cutaneous leishmaniasis—Implications for global prevalence and burden
- 391 of disease estimates. PLoS Negl Trop Dis. 2017;11(8):2–6.
- 392 4. Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, et al. Cutaneous
- 393 leishmaniasis and co-morbid major depressive disorder: A systematic review with burden
- 394 estimates. Boelaert M, editor. PLoS Negl Trop Dis [Internet]. 2019 Feb 25 [cited 2021 Apr
- 395 9];13(2):e0007092. Available from: https://dx.plos.org/10.1371/journal.pntd.0007092

- 396 5. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, et al. Short report:
- 397 Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med
- 398 Hyg [Internet]. 2010 Jan [cited 2021 Mar 26];82(1):9–11. Available from:
- 399 /pmc/articles/PMC2803501/
- 400 6. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Vol. 17,
- 401 Clinical Microbiology and Infection. Blackwell Publishing Ltd; 2011. p. 1471–7.
- 402 7. Pascual Martínez F, Picado A, Roddy P, Palma P. Low castes have poor access to visceral
- 403 leishmaniasis treatment in Bihar, India. Trop Med Int Heal [Internet]. 2012 May 1 [cited 2021
- 404 Jul 1];17(5):666–73. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-
- 405 3156.2012.02960.x
- 406 8. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Vol. 9, Asian Pacific Journal of
 407 Tropical Medicine. Elsevier (Singapore) Pte Ltd; 2016. p. 925–32.
- 408 9. Dantas-Torres F, Brandão-Filho SP. Visceral leishmaniasis in Brazil: Revisiting paradigms of
- 409 epidemiology and control. Vol. 48, Revista do Instituto de Medicina Tropical de Sao Paulo.
- 410 2006. p. 151–6.
- 411 10. Kamhawi S. The yin and yang of leishmaniasis control. Aksoy S, editor. PLoS Negl Trop Dis
- 412 [Internet]. 2017 Apr 20 [cited 2021 Apr 12];11(4):e0005529. Available from:
- 413 https://dx.plos.org/10.1371/journal.pntd.0005529
- 414 11. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine
- 415 research and development of vaccines for leishmaniasis. Vaccine. 2016 Jun 3;34(26):2992–5.
- 416 12. Kaye P. A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine
- 417 ChAd63-KH in PKDL [Internet]. ClinicalTrials.gov Identifier: NCT03969134. 2019 [cited 2021 Jul
- 418 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03969134
- 419 13. Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et al. A second
- 420 generation leishmanization vaccine with a markerless attenuated Leishmania major strain
- 421 using CRISPR gene editing. Nat Commun. 2020;11(1):1–14.

- 422 14. Malvolti S, Malhame M, Mantel C, Rutte EA Le, Kaye PM. Human leishmaniasis vaccines: use
- 423 cases, target population and potential global demand. PLoS Negl Trop Dis. 2021;Forthcoming.
- 424 15. The World Bank. New country classifications by income level: 2019-2020 [Internet]. World
- 425 Bank Blogs. 2019 [cited 2021 Apr 12]. Available from:
- 426 https://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020
- 427 16. GAVI. How to request new GAVI support. Geneva; 2019.
- 428 17. Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global distribution maps of
 429 the Leishmaniases. Elife. 2014 Jun 27;2014(3).
- 430 18. Nations U, of Economic D, Affairs S, Division P. World Population Prospects 2019, Volume I:
- 431 Comprehensive Tables.
- 432 19. Nations U, of Economic D, Affairs S, Division P. World Population Prospects 2019, Volume II:

433 Demographic Profiles [Internet]. 2019 [cited 2021 Apr 1]. Available from:

- 434 www.unpopulation.org.
- 435 20. Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, et al. Global age-
- 436 sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in
- 437 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the
- 438 Global Burden of Disease Study 2019. Lancet [Internet]. 2020 Oct 17 [cited 2021 Apr
- 439 1];396(10258):1160–203. Available from: http://www.
- 440 21. Heydarpour F, Sari AA, Mohebali M, Shirzadi M, Bokaie S. Incidence and Disability-Adjusted
- 441 Life Years (Dalys) Attributable to Leishmaniasis In Iran, 2013. Ethiop J Health Sci [Internet].
- 442 2016 Jul 1 [cited 2021 Apr 7];26(4):381–8. Available from: /pmc/articles/PMC4992778/
- 443 22. Cecílio P, Oliveira F, Silva AC da. Vaccines for Human Leishmaniasis: Where Do We Stand and
- 444 What Is Still Missing? In: Leishmaniases as Re-emerging Diseases. InTech; 2018. p. 59–79.
- 445 23. Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of
- 446 Leishmania vaccines: predicting the future from past and present experience. J Biomed Res
- 447 [Internet]. 2013 [cited 2021 Aug 13];27(2):85. Available from: /pmc/articles/PMC3602867/

- 448 24. Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, et al. Point-of-Care Viral
- 449 Load Testing for Sub-Saharan Africa: Informing a Target Product Profile. Open Forum Infect
- 450 Dis [Internet]. 2016 May 1 [cited 2021 Aug 19];3(3). Available from:
- 451 https://academic.oup.com/ofid/article/3/3/ofw161/2593307
- 452 25. Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, et al.
- 453 Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-
- 454 Income Countries. J Infect Dis [Internet]. 2015 Aug 15 [cited 2021 Aug 19];212(4):570–7.
- 455 Available from: https://academic.oup.com/jid/article/212/4/570/818811
- 456 26. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-
- 457 income countries: A novel approach and evidence from cross-country data. BMJ Glob Heal
- 458 [Internet]. 2018 Jan 1 [cited 2020 Jul 16];3(6):964. Available from:
- 459 http://dx.doi.org/10.1136/bmjgh-2018-000964
- 460 27. Lomas J, Claxton K, Ochalek J. Accounting for country- and time-specific values in the
- 461 economic evaluation of health-related projects relevant to low- and middle-income
- 462 countries. Health Policy Plan. 2021;Forthcoming.
- 463 28. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-
- 464 income countries: a novel approach and evidence from cross-country data. BMJ Glob Heal
- 465 [Internet]. 2018 [cited 2020 Jan 6];3:964. Available from: http://dx.doi.org/10.1136/bmjgh-
- 466 2018-000964
- 467 29. Micah AE, Su Y, Bachmeier SD, Chapin A, Cogswell IE, Crosby SW, et al. Health sector
- 468 spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance
- 469 for health: progress towards Sustainable Development Goal 3. Lancet [Internet]. 2020 Apr
- 470 [cited 2020 Jul 23];0(0). Available from: https://doi.org/10.1016/S0140-6736
- 471 30. Ochalek J, Claxton K, Lomas J, Thompson KM. Valuing health outcomes: developing better
- defaults based on health opportunity costs. https://doi.org/101080/1473716720201812387
- 473 [Internet]. 2020 [cited 2021 Aug 8]; Available from:

- 474 https://www.tandfonline.com/doi/abs/10.1080/14737167.2020.1812387
- 475 31. de Carvalho IPSF, Peixoto HM, Romero GAS, de Oliveira MRF. Cost of visceral leishmaniasis
- 476 care in Brazil. Trop Med Int Heal [Internet]. 2017 Dec 1 [cited 2021 Apr 7];22(12):1579–89.
- 477 Available from: http://doi.wiley.com/10.1111/tmi.12994
- 478 32. Eid Rodríguez D, San Sebastian M, Pulkki-Brännström A-M. "Cheaper and better": Societal
- 479 cost savings and budget impact of changing from systemic to intralesional pentavalent
- 480 antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia. Al-Salem WS,
- 481 editor. PLoS Negl Trop Dis [Internet]. 2019 Nov 6 [cited 2021 Apr 7];13(11):e0007788.
- 482 Available from: https://dx.plos.org/10.1371/journal.pntd.0007788
- 483 33. Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, et al. Re-evaluating the potential
- 484 impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.
- 485 Lancet Glob Heal. 2019 Dec 1;7(12):e1664–74.
- 486 34. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and
- 487 global estimates of its incidence [Internet]. Vol. 7, PLoS ONE. Public Library of Science; 2012

488 [cited 2021 Jul 1]. p. 35671. Available from: www.plosone.org

- 489 35. Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. Assessing the value of human papillomavirus
- 490 vaccination in Gavi-eligible low-income and middle-income countries. BMJ Glob Heal
- 491 [Internet]. 2020 Oct 20 [cited 2021 Mar 26];5(10):3006. Available from:
- 492 http://dx.doi.org/10.1136/bmjgh-2020-003006
- 493 36. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a
- 494 visceral leishmaniasis vaccine in Bihar State, India. Am J Trop Med Hyg [Internet]. 2012 Mar
- 495 [cited 2021 Mar 26];86(3):417–25. Available from: /pmc/articles/PMC3284356/
- 496 37. Biopharm. COVID-19 Adenovirus-Based Vaccine Supply Production Titre & Dosage Quantity
- 497 will be Critical to Achieve Global Access [Internet]. 2020 [cited 2021 Apr 8]. Available from:
- 498 https://www.biopharmservices.com/covid-19-adenovirus-based-vaccine-supply-production-
- 499 titre-dosage-quantity-will-be-critical-to-achieve-global-access/

- 500 38. Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, et al. Producing
- 501 Standardized Country-Level Immunization Delivery Unit Cost Estimates. Pharmacoeconomics
- 502 [Internet]. 2020 Sep 1 [cited 2021 Apr 12];38(9):995–1005. Available from:
- 503 https://doi.org/10.1007/s40273-020-00930-6
- 504 39. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal leishmaniasis: An
- 505 unresolved mystery [Internet]. Vol. 30, Trends in Parasitology. Elsevier; 2014 [cited 2021 Apr
- 506 9]. p. 65–74. Available from: /pmc/articles/PMC3919212/
- 507 40. Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, et al. Cutaneous
- 508 leishmaniasis and co-morbid major depressive disorder: A systematic review with burden
- 509 estimates. Boelaert M, editor. PLoS Negl Trop Dis [Internet]. 2019 Feb 25 [cited 2020 May
- 510 8];13(2):e0007092. Available from: http://dx.plos.org/10.1371/journal.pntd.0007092

512 Table 1: List of countries included in the analysis

		WHO	World Bank	Disease	GAVI support status
Country	Continent	Region	Income Level	endemicity	(2020)
Afghanistan	Asia	EMRO	Upper-middle	VL	Initial self-financing
Algeria	Africa	EMRO	Upper-middle	VL	Ineligible
Bangladesh	Asia	SEARO	Low	CL & VL	Preparatory transition
Brazil	South America	РАНО	Upper-middle	VL	Ineligible
China	Asia	WPRO	Lower-middle	CL & VL	Ineligible
Ethiopia	Africa	AFRO	High	CL	Initial self-financing
Georgia	Europe	EURO	Lower-middle	VL	Fully self-financing
India	Asia	SEARO	Lower-middle	CL	Accelerated transition
Israel	Asia	EURO	Lower-middle	VL	Ineligible
Kenya	Africa	AFRO	Lower-middle	CL	Preparatory transition
Morocco	Africa	EMRO	Lower-middle	CL	Ineligible
Nepal	Asia	SEARO	Upper-middle	VL	Initial self-financing
Nigeria	Africa	AFRO	High	CL	Accelerated transition

Pakistan	Asia	EMRO	Low	VL	Preparatory transition
Paraguay	South America	РАНО	Low	VL	Ineligible
Saudi Arabia	Asia	EMRO	High	VL	Ineligible
Somalia	Africa	EMRO	Low	CL & VL	Initial self-financing
South Sudan	Africa	EMRO	Low	CL	Initial self-financing
Spain	Europe	EURO	Lower-middle	CL	Ineligible
Sudan	Africa	AFRO	Upper-middle	CL	Preparatory transition
Syria	Asia	EMRO	Lower-middle	CL	Initial self-financing
Tunisia	Africa	EMRO	Upper-middle	VL	Ineligible
Turkey	Asia	EURO	Upper-middle	VL	Ineligible
Uzbekistan	Asia	EURO	Low	CL & VL	Accelerated transition

	Visceral Leishmaniasis								Cutaneous Leishmaniasis					
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)
Afghanistan	-				7.24	5.25	7.12	11,124,437	0.944%	2.129%	1.374%	0.17	0.42	1.30
Algeria	-				8.31	5.08	6.44	10,609,819	0.187%	0.383%	0.275%	0.03	0.03	0.03
Bangladesh	30,955,876	0.003%	0.002%	0.001%	16.32	10.40	13.77	-						
Brazil	82,117,821	0.020%	0.015%	0.005%	14.40	10.02	14.86	-				0.04	0.04	0.04
China	232,875,38 0	0.001%	0.001%	0.000%	0.02	0.02	0.02	-				0.03	0.04	0.09
Ethiopia	3,424,788	0.123%	0.099%	0.035%	23.72	17.04	17.28	5,455,824	0.002%	0.003%	0.002%	0.17	0.52	1.78
Georgia	2,580,002	0.009%	0.007%	0.002%	8.77	3.68	5.50	-				0.03	0.03	0.03

			Visceral Le	ishmaniasis						Cutaneous I	eishmaniasis.			
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)
India	134,094,34 7	0.017%	0.014%	0.004%	11.92	6.93	11.57	107,275,47 8	0.000%	0.000%	0.000%	0.12	0.45	1.24
Israel	-				7.06	4.04	5.80	8,971,638	0.002%	0.004%	0.004%	0.03	0.03	0.03
Kenya	3,501,646	0.075%	0.053%	0.018%	10.48	12.26	16.09	-				0.11	0.22	0.46
Morocco	-				6.44	5.31	6.72	6,364,300	0.134%	0.251%	0.149%	0.11	0.27	0.59
Nepal	29,942,425	0.002%	0.002%	0.001%	11.30	7.70	11.76	-						
Nigeria	-				26.32	17.98	13.73	3,238,811	0.000%	0.000%	0.001%	0.20	0.57	1.41
Pakistan	-				11.75	9.17	14.55	91,841,655	0.011%	0.021%	0.017%	0.14	0.40	1.29
Paraguay	3,180,239	0.004%	0.003%	0.001%	15.33	12.35	16.40	-				0.08	0.13	0.17
Saudi Arabia	-				8.70	4.34	5.94	3,794,820	0.028%	0.208%	0.343%	0.03	0.03	0.03

	Visceral Leishmaniasis								Cutaneous Leishmaniasis					
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)
Somalia	2,585,353	0.104%	0.080%	0.028%	17.72	16.24	15.52	-						
South Sudan	2,088,706	0.432%	0.345%	0.103%	21.24	14.36	13.96	-						
Spain	37,193,165	0.001%	0.000%	0.000%	7.12	4.27	5.99	-				0.03	0.03	0.03
Sudan	9,336,300	0.084%	0.068%	0.025%	7.37	4.40	6.54	40,171,954	0.004%	0.010%	0.008%	0.12	0.26	0.78
Syria	-				8.16	6.06	6.76	18,192,904	0.276%	0.911%	0.574%	0.08	0.12	0.16
Tunisia	-				7.36	4.41	6.03	6,220,910	0.184%	0.446%	0.283%	0.03	0.03	0.03
Turkey	-				8.97	4.96	5.86	43,467,592	0.015%	0.023%	0.013%	0.03	0.03	0.03
Uzbekistan	-				8.29	4.23	5.33	16,236,757	0.017%	0.021%	0.016%	0.03	0.03	0.03

517 Table 3: Value-based maximum price for a leishmaniasis vaccine course (2030-2040)

	Total demand for	Value-based maximum	Value-based maximum price
Country	vaccine courses (2030-	price per course (assuming	per course (assuming
	2040)	treatment coverage = 0%)	treatment coverage = 100%)
Afghanistan	12,963,289.41	7.25	13.41
Algeria	9,167,695.55	4.67	5.87
Bangladesh	11,450,264.05	1.81	2.03
Brazil	33,953,582.53	113.71	114.30
China	76,399,800.95	0.02	0.05
Ethiopia	9,532,973.75	24.16	25.36
Georgia	936,403.91	4.00	4.27
India	135,475,311.59	6.60	7.09
Israel	8,893,083.19	0.46	0.48
Kenya	3,369,092.01	41.74	43.89
Morocco	4,878,091.63	8.33	9.08
Nepal	11,517,484.52	1.45	1.64
Nigeria	5,015,541.10	0.01	0.01

Pakistan	101,103,820.38	0.18	0.25
Paraguay	2,078,491.89	29.23	29.36
Saudi Arabia	3,125,074.95	11.57	12.36
Somalia	1,585,208.80	8.65	19.82
South Sudan	1,049,268.43	115.09	159.44
Spain	10,171,505.03	5.55	5.57
Sudan	55,713,341.93	4.22	5.02
Syria	21,633,241.88	1.31	3.93
Tunisia	4,447,800.09	3.42	4.73
Turkey	23,864,258.55	0.83	0.90
Uzbekistan	15,730,232.81	0.09	0.16
	Median	4.44	5.29
	Mean	16.43	19.54

	With GAVI support			Efficacy = 50%		Efficacy = 95%		Und facto	Underreporting by a factor of 3.2 (CL) and 3.5 (VL)		Underreporting by a factor of 5.7 (CL) and 6.7 (VL)	
Country	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	VBI (assum treatm covera 0%	P ning nent Ige =)	VBP (assuming treatment coverage = 100%)	VBP (assumin treatmer coverage 0%)	lg ht =	VBP (assuming treatment coverage = 100%)	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)
Afghanistan	19.39	25.56	19.39	25.56	9.18		16.99	23.39		43.30	41.08	76.05
Algeria	4.67	5.87	4.67	5.87	5.92		7.44	15.08		18.96	26.48	33.30
Bangladesh	1.81	2.03	1.81	2.03	1.98		2.23	6.29		7.06	12.11	13.58
Brazil	113.71	114.30	113.71	114.30	144.	03	144.78	394.86		396.91	759.85	763.79
China	0.02	0.05	0.02	0.05	0.0	2	0.07	0.06		0.19	0.12	0.37
Ethiopia	24.16	25.36	24.16	25.36	30.6	50	32.12	83.89		88.06	161.40	169.42
Georgia	4.00	4.27	4.00	4.27	5.0	7	5.41	13.89		14.82	26.73	28.52
India	6.60	7.09	6.60	7.09	7.2	0	7.74	22.93		24.61	44.12	47.35
Israel	0.46	0.48	0.46	0.48	0.5	9	0.60	1.50		1.54	2.63	2.71
Kenya	41.74	43.89	41.74	43.89	52.8	38	55.60	144.96		152.42	278.95	293.31
Morocco	8.33	9.08	8.33	9.08	10.5	55	11.50	26.90		29.30	47.23	51.46
Nepal	1.45	1.64	1.45	1.64	1.5	9	1.80	5.05		5.69	9.71	10.95

520 Table 4: Value-based maximum price for a leishmaniasis vaccine course (2030-2040) – Sensitivity analyses

Nigeria	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.03	0.04	0.05
Pakistan	0.21	0.27	0.21	0.27	0.23	0.32	0.59	0.81	1.04	1.43
Paraguay	29.23	29.36	29.23	29.36	37.02	37.19	101.49	101.95	195.30	196.18
Saudi Arabia	11.57	12.36	11.57	12.36	14.65	15.66	37.33	39.91	65.56	70.09
Somalia	99.26	110.43	99.26	110.43	9.29	21.30	30.05	68.84	57.83	132.48
South Sudan	398.55	442.90	398.55	442.90	123.92	171.79	399.66	553.68	769.07	1,065.46
Spain	5.55	5.57	5.55	5.57	7.03	7.05	19.28	19.33	37.10	37.20
Sudan	4.22	5.02	4.22	5.02	4.60	5.48	14.63	17.40	28.10	33.42
Syria	1.63	4.24	1.63	4.24	1.66	4.97	4.23	12.68	7.43	22.26
Tunisia	3.42	4.73	3.42	4.73	4.33	5.99	11.04	15.27	19.39	26.81
Turkey	0.83	0.90	0.83	0.90	1.05	1.14	2.67	2.90	4.69	5.09
Uzbekistan	0.09	0.16	0.09	0.16	0.11	0.20	0.28	0.51	0.50	0.90
Median	4.44	5.29	3.41	3.81	5.49	6.52	14.85	18.18	27.41	33.36
Mean	32.54	35.65	12.31	14.94	19.73	23.22	56.67	67.34	108.19	128.42











